Healthcare DIVE November 6, 2024
Emily Olsen

Still, gross spending on the drugs increased by more than 500% from 2019 to 2023, according to the health policy research firm.

Dive Brief:

  • Few Medicaid programs cover GLP-1 drugs for obesity as states grapple with the medications’ high cost, according to an analysis by KFF.
  • Thirteen programs for the safety-net coverage include the newer glucagon-like peptide-1 drugs for weight loss as of August 2024, the health policy research firm found.
  • Still, GLP-1 prescriptions and spending in Medicaid are increasing quickly. From 2019 to 2023, the number of prescriptions spiked by more than 400%, while gross spending soared by more than 500%.

Dive Insight:

GLP-1s currently make up a small portion of Medicaid prescriptions and spending...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Pharma / Biotech, States, Survey / Study, Trends
Related Articles:
MACPAC calls for greater transparency amid steep rise in Medicaid directed payments
STAT+: Pharmalittle: We’re reading about Medicaid coverage of obesity drugs, a death in a sickle cell trial, and more
Medicaid covers GLP-1 meds for obesity in just 13 states, analysis finds
Building A Longitudinal Community Supports Model
Medicaid Coverage of and Spending on GLP-1s

Share This Article